Dova Pharmaceuticals Inc. (DOVA) and Cellect Biotechnology Ltd. (NASDAQ:APOP) Comparison side by side

Since Dova Pharmaceuticals Inc. (NASDAQ:DOVA) and Cellect Biotechnology Ltd. (NASDAQ:APOP) are part of the Biotechnology industry, they are influenced by contrast. The influences particularly affect the analyst recommendations, profitability, risk, dividends, institutional ownership, earnings and valuation of both companies.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Dova Pharmaceuticals Inc. 7.51M 29.02 62.25M -2.27 0.00
Cellect Biotechnology Ltd. N/A 0.00 N/A -0.85 0.00

In table 1 we can see Dova Pharmaceuticals Inc. and Cellect Biotechnology Ltd.’s top-line revenue, earnings per share and valuation.

Profitability

Table 2 shows us Dova Pharmaceuticals Inc. and Cellect Biotechnology Ltd.’s return on assets, net margins and return on equity.

Net Margins Return on Equity Return on Assets
Dova Pharmaceuticals Inc. -828.89% -63.8% -50.2%
Cellect Biotechnology Ltd. 0.00% 0% 0%

Institutional & Insider Ownership

Dova Pharmaceuticals Inc. and Cellect Biotechnology Ltd. has shares held by institutional investors as follows: 47.7% and 0%. Insiders held 44.9% of Dova Pharmaceuticals Inc. shares. Competitively, Cellect Biotechnology Ltd. has 54.73% of it’s share held by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Dova Pharmaceuticals Inc. 3.62% -17.48% -33.99% -47.8% -48.29% -46.39%
Cellect Biotechnology Ltd. -4.19% -33.88% -35.74% -56.13% -57.5% -54.29%

For the past year Dova Pharmaceuticals Inc. was less bearish than Cellect Biotechnology Ltd.

Summary

Cellect Biotechnology Ltd. beats Dova Pharmaceuticals Inc. on 5 of the 9 factors.

Dova Pharmaceuticals, Inc., a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia diseases. Its drug candidate includes avatrombopag, an orally administered thrombopoietin receptor agonist that has completed Phase III clinical trials for the treatment of thrombocytopenia in patients with chronic liver diseases. The company was founded in 2016 and is based in Durham, North Carolina.

Cellect Biotechnology Ltd., a biotechnology company, focuses on developing technologies for the functional selection of stem cells in the field of regenerative medicine and stem cell therapies in Israel. It is developing the Apotainer selection kit, a shelf stem cell selection kit, based on its Powered by Cellect technology platform for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies. The company was founded in 2011 and is headquartered in Kfar Saba, Israel.